BMS-599626 HydrochlorideEGFR/HER2 inhibitor,potent and selective CAS# 873837-23-1 |
- Lapatinib
Catalog No.:BCC3633
CAS No.:231277-92-2
- Lapatinib Ditosylate
Catalog No.:BCC2083
CAS No.:388082-78-8
- Neratinib (HKI-272)
Catalog No.:BCC3685
CAS No.:698387-09-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 873837-23-1 | SDF | Download SDF |
| PubChem ID | 46930994 | Appearance | Powder |
| Formula | C27H28ClFN8O3 | M.Wt | 567.01 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | AC480 | ||
| Solubility | DMSO : 100 mg/mL (176.36 mM; Need ultrasonic) | ||
| Chemical Name | [(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate;hydrochloride | ||
| SMILES | CC1=C2C(=NC=NN2C=C1NC(=O)OCC3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F.Cl | ||
| Standard InChIKey | COUSSRGSHIJMMN-FTBISJDPSA-N | ||
| Standard InChI | InChI=1S/C27H27FN8O3.ClH/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18;/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33);1H/t22-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc.
IC50 value: 20 nM (HER1); 30 nM (HER2) [1]
Target: HER1/HER2
in vitro: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, respectively, and was highly selective when tested against a broad panel of diverse protein kinases. Biochemical studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms. BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 micromol/L. BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors. In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling [1]. At the molecular level, in HN-5 cells the agent inhibited the expression of pEGFR, pHER2, cyclins D and E, pRb, pAkt, pMAPK, pCDK1 and 2, CDK 6, and Ku70 proteins. The drug also induced accumulation of cells in the G1 cell cycle phase, inhibited cell growth, enhanced radiosensitivity, and prolonged the presence of γ-H?AX foci up to 24 h after radiation [2].
in vivo: BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity [1]. The drug given before and during irradiation improved the radioresponse of HN5 tumors in vivo [2]. References: | |||||
BMS-599626 Hydrochloride Dilution Calculator
BMS-599626 Hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7636 mL | 8.8182 mL | 17.6364 mL | 35.2727 mL | 44.0909 mL |
| 5 mM | 0.3527 mL | 1.7636 mL | 3.5273 mL | 7.0545 mL | 8.8182 mL |
| 10 mM | 0.1764 mL | 0.8818 mL | 1.7636 mL | 3.5273 mL | 4.4091 mL |
| 50 mM | 0.0353 mL | 0.1764 mL | 0.3527 mL | 0.7055 mL | 0.8818 mL |
| 100 mM | 0.0176 mL | 0.0882 mL | 0.1764 mL | 0.3527 mL | 0.4409 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BMS-599626 is a selective inhibitor of HER1 and HER2 with IC50 value of 22 nM and 32 nM, respectively [1].
HER (human epidermal growth factor receptor) is a member of EGFR/ErbB family and plays an important role in transduction of cell proliferation and differentiation. It has been reported that abbrent expression of HER is correlated with cancer and HER inhibition is being regarded as a promising strategy for cancer treatment [1].
BMS-599626 is a potent HER inhibitor and has the higher inhibition ability than the other reported inhibitors. When tested with breast tumor cell lines (HCC202, HCC1942 and AU565) that highly expressing HER1 and HER2, BMS-599626 treatment inhibited cell proliferation, while had no effect on A2780 cells that without HER1 or HER2 expression [1]. Treated OV202 cells with BMS-599626 significantly inhibited cell proliferation and enhanced cell apoptosis by inhibiting HER [2].
In mouse model with Sal2 tumor cells xenograft, oral administration of BMS-599626 inhibited Sal2 cells growth in a dose-dependent manner and significantly delayed tumor growth at the concentration of 60 mg/kg [1].
When tested with Sal2 cells expressing CD8-HER2 fusion protein, BMS-599626 treatment inhibited the receptor phosphorylation and MAPK phosphorylation with the IC50 value of 0.3 and 0.22 μM/L, respectively [1].
References:
[1].Wong, T.W., et al., Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res, 2006. 12(20 Pt 1): p. 6186-93.
[2].Haluska, P., et al., HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther, 2008. 7(9): p. 2589-98.
- TATU
Catalog No.:BCC2822
CAS No.:873798-09-5
- PLX647
Catalog No.:BCC6370
CAS No.:873786-09-5
- Omecamtiv mecarbil
Catalog No.:BCC3710
CAS No.:873697-71-3
- Demethylcarolignan E
Catalog No.:BCN7018
CAS No.:873694-46-3
- GDC-0152
Catalog No.:BCC2252
CAS No.:873652-48-3
- Lupeolic acid
Catalog No.:BCN6520
CAS No.:87355-32-6
- PU-H71
Catalog No.:BCC1872
CAS No.:873436-91-0
- Triangularine
Catalog No.:BCN2051
CAS No.:87340-27-0
- Fortuneine
Catalog No.:BCN6401
CAS No.:87340-25-8
- TC-P 262
Catalog No.:BCC6155
CAS No.:873398-67-5
- 1,7-Dihydroxy-4-methoxyxanthone
Catalog No.:BCN7602
CAS No.:87339-76-2
- Ramipril
Catalog No.:BCC5012
CAS No.:87333-19-5
- Fidaxomicin
Catalog No.:BCC4660
CAS No.:873857-62-6
- 3,4,5'-Trimethoxy-3',4'-methylenedioxy-7,9':7',9-diepoxylignan
Catalog No.:BCN7238
CAS No.:873867-94-8
- Neotriangularine
Catalog No.:BCN2052
CAS No.:87392-67-4
- 2,3-Dihydroamentoflavone 7,4'-dimethyl ether
Catalog No.:BCN1320
CAS No.:873999-88-3
- Denudatin B
Catalog No.:BCN4558
CAS No.:87402-88-8
- Euchrestaflavanone B
Catalog No.:BCN6838
CAS No.:87402-91-3
- RO4987655
Catalog No.:BCC5135
CAS No.:874101-00-5
- Daphnilongeranin A
Catalog No.:BCN4418
CAS No.:874201-05-5
- Liriopesides B
Catalog No.:BCN2811
CAS No.:87425-34-1
- Millewanin G
Catalog No.:BCN6461
CAS No.:874303-33-0
- Millewanin H
Catalog No.:BCN6465
CAS No.:874303-34-1
- Glepidotin B
Catalog No.:BCN4844
CAS No.:87440-56-0
Small molecules with EGFR-TK inhibitor activity.[Pubmed:15857287]
Curr Drug Targets. 2005 May;6(3):259-74.
Specific and reversible EGFR tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib are clinically active in advanced or metastatic NSCLC and both are approved in various countries for the treatment of patients that failed prior chemotherapy. Erlotinib has also prolonged survival in pancreatic cancer patients when added to gemcitabine and regulatory approval in this disease is being sought. Additional promising activity has been seen in other tumor types, such as ovarian cancer or head and neck malignancies, and phase III trials in these malignancies are ongoing or planned. Despite these successes, these agents have exhibited anecdotal or modest activity when used as single agents in unselected patients with various other tumor types. We have learned that the clinical development of these agents is far from simple and we need to better understand biological and clinical criteria for patient selection and how to best use the different available agents. The recent discovery of EGFR mutations and the potential identification of other markers that might predict patient response could help to optimize the use of these agents in the future. Irreversible EGFR inhibitors, dual EGF/HER2 and pan-ErbB receptor inhibitors may have greater antitumor activity although the tolerance of these compounds compared to specific EGFR TKIs needs further characterization. HER2 specific TKIs are also in development. Lapatinib, a dual EGFR/HER2 TK inhibitors, is particularly promising in breast cancer. Newer agents, such as BMS-599626, have recently entered into the clinic. In addition to the use of these agents as single agents, many clinical studies are addressing the role of combining them with hormonal agents, biological agents or chemotherapy.
